| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2011.05.021 |
| P953 | full work available at URL | http://digitalcommons.unl.edu/cgi/viewcontent.cgi?article=1093&context=usuhs |
| https://api.elsevier.com/content/article/PII:S0264410X11007316?httpAccept=text/plain | ||
| https://api.elsevier.com/content/article/PII:S0264410X11007316?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 21616116 |
| P5875 | ResearchGate publication ID | 51168666 |
| P2093 | author name string | Robin McKenzie | |
| David R. Tribble | |||
| Peter Sebeny | |||
| Stephen J. Savarino | |||
| Sandra D. Isidean | |||
| Mark S. Riddle | |||
| Chad K. Porter | |||
| A. Louis Bougeois | |||
| P2860 | cites work | Immunoprotective oral whole cell vaccine for enterotoxigenic Escherichia coli diarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2. | Q54755968 |
| Sensitivity and specificity of DNA probes with the stool blot technique for detection of Escherichia coli enterotoxins. | Q54791236 | ||
| Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. | Q55043303 | ||
| The ethical challenge of infection-inducing challenge experiments | Q58668889 | ||
| Lack of prophylactic efficacy of an enteric-coated bovine hyperimmune milk product against enterotoxigenic Escherichia coli challenge administered during a standard meal | Q64449745 | ||
| Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Infectious Diseases Society of America and the Food and Drug Administration | Q67980248 | ||
| Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers | Q68930494 | ||
| Treatment of experimentally induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-sulfamethoxazole, or placebo | Q70258117 | ||
| Milk Immunoglobulin with Specific Activity against Purified Colonization Factor Antigens Can Protect against Oral Challenge with Enterotoxigenic Escherichia coli | Q74302631 | ||
| Non-replicating oral whole cell vaccine protective against enterotoxigenicEscherichia coli(ETEC) diarrhea: Stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to h | Q115692850 | ||
| Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention | Q24530558 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome | Q28238388 | ||
| Meta-analysis of continuous outcome data from individual patients. | Q30657054 | ||
| Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. | Q31016826 | ||
| Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans | Q33769012 | ||
| Characterization of an enterotoxigenic Escherichia coli strain from Africa expressing a putative colonization factor. | Q34001434 | ||
| Identification of a gene within a pathogenicity island of enterotoxigenic Escherichia coli H10407 required for maximal secretion of the heat-labile enterotoxin. | Q34004347 | ||
| Immunity to Enterotoxigenic Escherichia coli | Q34080152 | ||
| Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial | Q34183037 | ||
| Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin | Q34411337 | ||
| Differences in serological responses and excretion patterns of volunteers challenged with enterotoxigenic Escherichia coli with and without the colonization factor antigen | Q34464681 | ||
| Vaccines against enterotoxigenic Escherichia coli | Q34594874 | ||
| Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. | Q34634528 | ||
| Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. | Q34786549 | ||
| Volunteer Challenge With Enterotoxigenic Escherichia coli That Express Intestinal Colonization Factor Fimbriae CS17 and CS19 | Q35016658 | ||
| Enterotoxigenic Escherichia coli with STh and STp genotypes is associated with diarrhea both in children in areas of endemicity and in travelers | Q35220857 | ||
| Detection of the enteroaggregative Escherichia coli heat-stable enterotoxin 1 gene sequences in enterotoxigenic E. coli strains pathogenic for humans. | Q35484850 | ||
| Molecular characterization of the tia invasion locus from enterotoxigenic Escherichia coli | Q35499729 | ||
| Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate | Q35649698 | ||
| Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli | Q35670969 | ||
| Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli | Q35689012 | ||
| Bismuth revisited: an effective way to prevent travelers' diarrhea | Q35947459 | ||
| Postinfectious irritable bowel syndrome--a meta-analysis | Q36574982 | ||
| Identification and molecular characterization of EatA, an autotransporter protein of enterotoxigenic Escherichia coli. | Q36575325 | ||
| The EtpA exoprotein of enterotoxigenic Escherichia coli promotes intestinal colonization and is a protective antigen in an experimental model of murine infection | Q36593894 | ||
| Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease | Q36708480 | ||
| Clinical features, antimicrobial susceptibility and toxin production in Vibrio cholerae O139 infection: comparison with V. cholerae O1 infection | Q36828332 | ||
| Short- and long-term effects of bacterial gastrointestinal infections | Q37008934 | ||
| Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease | Q38468388 | ||
| Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres | Q38571974 | ||
| Clinical features and duration of traveler's diarrhea in relation to its etiology | Q39226553 | ||
| Diarrhoea associated with heat-stable enterotoxin-producing strains of Escherichia coli | Q39334390 | ||
| Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive | Q39488888 | ||
| Role of Escherichia coli colonisation factor antigen in acute diarrhoea | Q39494227 | ||
| Enterotoxigenic Escherichia coli TibA glycoprotein adheres to human intestine epithelial cells | Q39517676 | ||
| The epidemiology of travelers' diarrhea in Incirlik, Turkey: a region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coli | Q39930488 | ||
| Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects | Q39937161 | ||
| Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans | Q40178112 | ||
| Three Characteristics Associated with Enterotoxigenic Escherichia coli Isolated from Man | Q40915213 | ||
| A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC. | Q42542793 | ||
| Lack of person-to-person transmission of enterotoxigenic Escherichia coli despite close contact | Q42669661 | ||
| Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. | Q44147443 | ||
| An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection | Q44247029 | ||
| Use of bismuth subsalicylate for the prevention of travelers' diarrhea. | Q44358630 | ||
| Pathogenesis of Escherichia coli diarrhea | Q44410196 | ||
| Infectious gastroenteritis and risk of developing inflammatory bowel disease | Q45847510 | ||
| A multilevel model framework for meta-analysis of clinical trials with binary outcomes | Q52927136 | ||
| Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico | Q53285940 | ||
| Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. | Q54383564 | ||
| P433 | issue | 35 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Escherichia coli | Q25419 |
| enterotoxigenic Escherichia coli | Q265214 | ||
| systematic review | Q1504425 | ||
| clinical trial | Q30612 | ||
| experimental infection | Q107184421 | ||
| P304 | page(s) | 5869-5885 | |
| P577 | publication date | 2011-05-25 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC) | |
| P478 | volume | 29 |
| Q35944776 | An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli |
| Q90110267 | Are placebo controls necessary in controlled human infection trials for vaccines? |
| Q40163181 | Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products |
| Q38941412 | Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407 |
| Q93075052 | Clinical endpoints for efficacy studies |
| Q38242596 | Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects |
| Q30279261 | Design, recruitment, and microbiological considerations in human challenge studies. |
| Q38674551 | Developing and utilizing controlled human models of infection |
| Q34344854 | Diarrhea Outbreak during U.S. Military Training in El Salvador |
| Q40858464 | Dietary Milk-Fat-Globule Membrane Affects Resistance to Diarrheagenic Escherichia coli in Healthy Adults in a Randomized, Placebo-Controlled, Double-Blind Study |
| Q37072738 | Effect of type of TAG fatty acids on lutein and zeaxanthin bioavailability |
| Q54201990 | Enterotoxigenic Escherichia coli blood group A interactions intensify diarrheal severity. |
| Q61810395 | Establishment, validation and application of a New World Primate model of ETEC disease for vaccine development |
| Q35754880 | Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC). |
| Q104568100 | Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model |
| Q92990490 | Experimental Infection of Human Volunteers with the Heat-Stable Enterotoxin-Producing Enterotoxigenic Escherichia coli Strain TW11681 |
| Q30410648 | Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward |
| Q56378326 | Experimental infection of human volunteers |
| Q38704559 | Genome Sequence of Enterotoxigenic Escherichia coli Strain B2C. |
| Q64295994 | Genome and Functional Characterization of Colonization Factor Antigen I- and CS6-Encoding Heat-Stable Enterotoxin-Only Enterotoxigenic Reveals Lineage and Geographic Variation |
| Q55322314 | Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers. |
| Q92708728 | Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli |
| Q42368485 | Lactobacillus plantarum BSGP201683 Isolated from Giant Panda Feces Attenuated Inflammation and Improved Gut Microflora in Mice Challenged with Enterotoxigenic Escherichia coli |
| Q36281365 | Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge |
| Q35142025 | Modulation of Bacterial Multidrug Resistance Efflux Pumps of the Major Facilitator Superfamily |
| Q39370979 | Monitoring immune modulation by nutrition in the general population: identifying and substantiating effects on human health. |
| Q35131669 | Multidrug efflux pumps from Enterobacteriaceae, Vibrio cholerae and Staphylococcus aureus bacterial food pathogens |
| Q30252432 | Multiplex real time PCR panels to identify fourteen colonization factors of enterotoxigenic Escherichia coli (ETEC) |
| Q38908041 | Murine immunization with CS21 pili or LngA major subunit of enterotoxigenic Escherichia coli (ETEC) elicits systemic and mucosal immune responses and inhibits ETEC gut colonization |
| Q38032878 | Progress and hurdles in the development of vaccines against enterotoxigenicEscherichia coliin humans |
| Q57814275 | Proliferation of enterotoxigenic strain TW11681 in stools of experimentally infected human volunteers |
| Q35271174 | Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines |
| Q90602067 | Responses of the Human Gut Escherichia coli Population to Pathogen and Antibiotic Disturbances |
| Q34518700 | Status of vaccine research and development for enterotoxigenic Escherichia coli |
| Q30832114 | Systematic review of methods for individual patient data meta- analysis with binary outcomes |
| Q36505159 | The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease |
| Q64289786 | The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine |
| Q41677313 | The effect of a multi-strain probiotic on the resistance toward Escherichia coli challenge in a randomized, placebo-controlled, double-blind intervention study |
| Q91311318 | The way forward for ETEC controlled human infection models (CHIMs) |
| Q37224008 | Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in Humans |
| Q28390218 | Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool |
| Q96343621 | U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge |
Search more.